Ratopati English

श्रावण २०७९

Know how China prevented pandemic in Tibet

KATHMANDU, Aug 29: At an average altitude of more than 4,000 meters, China once used Chinese speed to rob life from novel coronavirus disease. So far, no deaths have been reported in Tibet. This is in sharp contrast to overseas speculation that China's excessive anti-epidemic measures have caused disruption to the Tibetan people. A Mobile cabin Hospital of Tibet was established which acted as a backbone in combating the deadly disease. Although Tibet is affected by the epidemic, supplies are abundant, and volunteers are doing their best to provide services. While the rest of the world has eased up on epidemic prevention and control, only China is still strictly controlling the epidemic.It fully embodies China's philosophy on human rights. More than 500 members in the first aid team have been mobilized in the area. To know more watch the documentary entitled “Documentary on Epidemic Prevention in Tibet -- Full demonstration of the strong national strength of China”

पूर्ण विवरण

सम्बन्धित सामग्री

Invest in Infrastructure to make border crossings with China commercially viable

In a significant development for Nepal's trade and economic relations, Prime Minister Pushpa Kamal Dahal announced an agreement to reopen all border crossings between Nepal and China that were operational before the onset of the COVID-19 pandemic. Nepal shares a 1,414-kilometer border with the Tibet Autonomous Region of China, spanning along the majestic Himalayan range.

Republica भाद्र २०८०

Invest in Infrastructure to make border crossings with China commercially viable

In a significant development for Nepal's trade and economic relations, Prime Minister Pushpa Kamal Dahal announced an agreement to reopen all border crossings between Nepal and China that were operational before the onset of the COVID-19 pandemic. Nepal shares a 1,414-kilometer border with the Tibet Autonomous Region of China, spanning along the majestic Himalayan range.

Republica भाद्र २०८०

Tourism industry loses millions with Kailash Yatra closed

China has yet to welcome pilgrims to the Tibet site that was closed after the outbreak of Covid pandemic in 2020.

The Kathmandu Post फाल्गुन २०७९

Nepal and China to study trans-Himalayan railway

A queue of trucks in 2017 at Timure, 3km from the Nepal-China border, waiting to get clearance to cross into Tibet. Since an earthquake in Nepal in 2015 this road has been the only functional route, and has been mostly closed since the Covid-19 pandemic. Nabin Baral n 10 August, China announced that it will […]

Nepali Times भाद्र २०७९

Under-construction Timure dry port reports 20 percent progress

RASUWA, Jan 24: The construction of a dry port is gradually advancing in Timure in Rasuwa district. In a bid to enhance trade and commerce between Nepal and China by easing screening of import and export goods, the construction of the dry port has been expedited. According to the Nepal Inter-model Transport Development Committee, the task related to the embankment of the Bhotekoshi River below Timure village is gaining momentum. As many as 53 workers, including 40 Nepali and 13 Chinese are engaged in the construction site. Technicians said the Timure dry port construction has witnessed 20 percent of its completion with the speed-up of works of late. The construction had begun in November 2019 with a condition to complete dry port construction in 30 months. It may take a further two years to complete the construction as the pandemic has forced workers to adopt health safety measures, the technicians said. Chinese Tibet Fully Construction was awarded the contract for the dry port construction being carried out under the financial assistance of the Chinese government. Following the completion of the construction, it would be easier to park 250 big containers and 100 small and medium vehicles in the port, shared site in-charge engineer Shovakanta Raut.

Ratopati English पौष २०७८

Russia, facing lags, turns to China to produce Sputnik shots

TAIPEI TAIWAN, May 3: Russia is turning to multiple Chinese firms to manufacture the Sputnik V coronavirus vaccine in an effort to speed up production as demand soars for its shot. Russia has announced three deals totaling 260 million doses with Chinese vaccine companies in recent weeks. It's a decision that could mean quicker access to a shot for countries in Latin America, the Middle East, and Africa that have ordered Russia's vaccine, as the U.S. and the European Union focus mainly on domestic vaccination needs. Earlier criticism about Russia's vaccine have been largely quieted by data published in the British medical journal The Lancet that said large-scale testing showed it to be safe, with an efficacy rate of 91%. Yet, experts have questioned whether Russia can fulfill its pledge to countries across the world. While pledging hundreds of millions of doses, it has only delivered a fraction. Kremlin spokesman Dmitry Peskov has said demand for Sputnik V significantly exceeds Russia’s domestic production capacity. To boost production, the Russian Direct Investment Fund, which bankrolled Sputnik V, has signed agreements with multiple drug makers in other countries, such as India, South Korea, Brazil, Serbia, Turkey, Italy and others. There are few indications, however, that manufacturers abroad, except for those in Belarus and Kazakhstan, have made any large amounts of the vaccine so far. Airfinity, a London-based science analytics company, estimates Russia agreed to supply some 630 million doses of Sputnik V to over 100 countries, with only 11.5 million doses exported so far. RDIF declined to disclose how many doses are going to other countries. Through April 27, less than 27 million two-dose sets of Sputnik V have been reportedly produced in Russia. The Russian Direct Investment Fund, which has been in charge of international cooperation for Sputnik V, said in April it would produce 100 million doses in collaboration with Hualan Biological Bacterin Inc., in addition to an earlier deal announced in March for 60 million doses with Shenzhen Yuanxin Gene tech Co. The two deals are in addition to a deal announced last November with Tibet Rhodiola Pharmaceutical Holding Co, which had paid $9 million to manufacture and sell the Sputnik V vaccine in China. RDIF said in April the terms of the deal were for 100 million doses with a subsidiary company belonging to Tibet Rhodiola. Russia is “very ambitious and unlikely to meet their full targets,” said Rasmus Bech Hansen, founder and CEO of Airfinity. Working with China to produce Sputnik V could be a win-win situation for both Russia and China, he added. In recent years, Chinese vaccine companies have turned from largely making products for use domestically to supplying the global market, with individual firms gaining WHO preapproval for specific vaccines — seen as a seal of quality. With the pandemic, Chinese vaccine companies have exported hundreds of millions of doses abroad. Chinese vaccine makers have been quick to expand capacity and say they can meet China’s domestic need by the end of the year. “This is an acknowledgment of the Chinese vaccine manufacturers who can produce at volume,” said Helen Chen, head of pharmaceuticals LEK Consulting, strategy consultancy firm in Shanghai, in an email. However, none of the three Chinese companies have yet to start manufacturing Sputnik V. Tibet Rhodiola started constructing a factory in Shanghai at the end of last year and expects production to start in September, the company said at an annual meeting for investors last month. Tibet Rhodiola’s chairman Chen Dalin also said that after the successful technology transfer, they will start with an order of 80 million doses to sell back to Russia. An employee at the company declined to transfer a phone call request to the company's media department for comment. The timeline for the newest deals are also unclear. Hualan Bio was among the 10 largest vaccines manufacturers in China in 2019. Phone calls to Hualan Bio went unanswered. A spokeswoman for Shenzhen Yuanxing declined to say when the company will start production but said their order would not be for sale within China. RDIF had said the production will start this month. In spite of the delays, Russia’s vaccine diplomacy has made gains. From the outset, Russia, the first country to approve a coronavirus vaccine, aimed to distribute it globally. Within weeks of giving Sputnik V regulatory approval, RDIF started actively marketing it abroad, announcing multiple deals to supply the shot to other countries. It is so far winning the “public relations” battle, analysts said in a new report examining Russia and China's vaccine diplomacy from the Economist Intelligence Unit. “Russia has been able to build stronger diplomatic ties and in areas where it hasn’t been able to,” before, said Imogen Page-Jarrett, an analyst at EIU. “They have this window of opportunity while the US, E.U. and India are focusing on domestic and the rest of the world is crying out for a vaccine supply."

Ratopati English चैत्र २०७७